Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase®

Florentia Kaguelidou (), Zaba Valtuille, Geneviève Durrieu, Richard Delorme, Hugo Peyre, Jean-Marc Treluyer, François Montastruc and Laurent Chouchana
Additional contact information
Florentia Kaguelidou: Robert Debre Hospital, Paris Cité University
Zaba Valtuille: Robert Debre Hospital, Paris Cité University
Geneviève Durrieu: Toulouse University Hospital (CHU)
Richard Delorme: Paris Cité University
Hugo Peyre: Paris Cité University
Jean-Marc Treluyer: Paris Cité University
François Montastruc: Toulouse University Hospital (CHU)
Laurent Chouchana: Paris Cité University

Drug Safety, 2023, vol. 46, issue 1, No 6, 77-85

Abstract: Abstract Introduction While antipsychotic-induced weight gain has been widely described in adults, it has yet to be better characterized in children and adolescents. Objective The aim of this study was to assess antipsychotic-induced weight-gain reporting in children and adolescents as compared to adults, and according to the type of antipsychotic. Methods The study is an observational, case–non-case study using individual case safety reports from the WHO global pharmacovigilance database VigiBase® from 1 January 2000 to 2 June 2021. Disproportionality in antipsychotic-related weight-gain reporting in children and adolescents compared to adults was evaluated based on reporting odds ratios (RORs) with corresponding 95% confidence intervals (CIs) through multivariate logistic regression modeling. Analysis was adjusted for sex, region of reporting, year of notification, reporter qualification, concomitant use of antidepressants, and use of more than one antipsychotic. Results Among 282,224 antipsychotic-related spontaneous reports included in this analysis, we identified 16,881 (6.0%) weight-gain cases. Disproportionality in weight-gain reporting was found in children (adjusted ROR (aROR) 3.6; 95% CI 3.3–3.8) and in adolescents (aROR 2.3; 95% CI 2.2–2.4) compared to adults. Use of risperidone was associated with the highest increase in weight-gain reporting in children (aROR 4.9; 95% CI 3.9–6.1) and adolescents (aROR 3.6; 95% CI 3.1–4.1). Conclusions Compared to adults, weight-gain reporting with antipsychotics was disproportionally higher in the pediatric population, especially in children under 12 years of age. Considering the impact of weight gain on global morbidity and mortality, physicians should closely monitor weight gain in young patients, especially children on risperidone.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-022-01252-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:46:y:2023:i:1:d:10.1007_s40264-022-01252-6

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-022-01252-6

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().